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Abstract: Catastrophic chemical or radiological events can cause thousands of casualties. 
Such disasters require triage procedures to identify the development of health consequences 
requiring medical intervention. Our objective is to analyze recent advancements in 
biotechnology for triage in mass emergency situations. In addition to identifying persons 
“at risk” of developing health problems, these technologies can aid in securing the 
unaffected or “worried well”. We also highlight the need for public/private partnerships to 
engage in some of the underpinning sciences, such as patho-physiological mechanisms of 
chemical and radiological hazards, and for the necessary investment in the development of 
rapid assessment tools through identification of biochemical, molecular, and genetic 
biomarkers to predict health effects. For chemical agents, biomarkers of neurotoxicity, 
lung damage, and clinical and epidemiological databases are needed to assess acute and 
chronic effects of exposures. For radiological exposures, development of rapid, sensitive 
biomarkers using advanced biotechnologies are needed to sort exposed persons at risk of 
life-threatening effects from persons with long-term risk or no risk. The final implementation 
of rapid and portable diagnostics tools suitable for emergency care providers to guide 
OPEN ACCESSInt. J. Environ. Res. Public Health 2011, 8 
 
 
4522
triage and medical countermeasures use will need public support, since commercial 
incentives are lacking. 
Keywords: mass casualties; triage; biomarkers; biotechnology; diagnostic;   
chemical; radioactive 
 
1. Introduction—Mass Casualties Following Chemical or Radiological Exposures and the Use of 
Diagnostic Tools Based on Biotechnology 
A catastrophic event, involving chemical and/or radiological compounds or devices, may cause 
mass casualties in the order of several thousand. In the case of individual exposures, any number of 
resources can be utilized to diagnose and treat a patient (Figure 1). However, in a mass casualty event, 
the number of potentially affected persons involved will quickly overwhelm the available resources. 
Therefore, any such disaster would require some form of early screening to accurately and effectively 
identify and differentiate among patients so that as resources become scarcer they may be used more 
effectively. It is most critical that those patients likely to develop health consequences, requiring 
medical evaluation and intervention can be identified. A primary function of such screening could be 
to sort the unaffected, or “worried-well”, from those patients who soon will truly become symptomatic. 
Of those likely to become symptomatic, early assessments may also aid in predicting the severity of 
later health impairments. It may also guide health care personnel (physicians, nurses, etc.) to early and 
effective medical countermeasures and treatments. In addition, initial screening may also predict the 
likelihood of later, “stochastic” health impairments up to several years after the initial event. 
Identifying unaffected individuals is also extremely valuable in order to optimize the use of precious 
medical resources but also because unnecessary treatments can in some cases are deleterious.   
In accidents involving only a few persons that are treated in local hospitals, follow-up is fairly 
straightforward. In the mass casualty setting, the massive number of patients will require many local 
medical resources. Patients may be examined and treated in the field or at any number of different 
medical facilities in the vicinity, resulting in a significant logistical challenge for patient follow-up and 
tracking. Triage and early diagnostic screening, however, provides a mechanism for patient tracking 
for subsequent follow-up. 
Figure 1. Conceptual flow chart for exposure assessment of mass casualties. 
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This review evolves in part from the project Mass casualties and Health care following the release 
of toxic chemicals or radioactive material, (MASH) supported by Directorate General for Health issues 
of the European Union, DG Sanco. It summarizes and comments on methods and tools made available 
from recent advancements in biotechnology to triage mass emergency situations following exposure to 
toxic chemicals and/or to dangerous radioactive material. Current methods for early diagnostics and 
exposure assessment are summarized giving particular attention to those methods able to indicate 
probable health consequences, latent effects, and/or the need for medical treatments. A horizon scan 
into the fields of molecular diagnostics, proteomics and genomics will are also be made, highlighting 
particularly promising developments that should be of critical value to the mass emergency situation. 
The use of electronic, standardized medical algorithms to support medical personnel in the triage 
situation is reviewed. 
1.1. C and R Threats and Events 
Threat scenarios involving chemicals include the deliberate release of illegally obtained or 
manufactured chemical warfare agents, the release of purchased or stolen industrial chemicals, and 
attacks on chemical manufacturing plants, storage sites, or transport vehicles. Moreover, the potential 
also exists for the malicious use of chemicals to contaminate food or water sources. In the same 
manner as described for toxic chemicals, radioactive materials may also be used for malicious purposes. 
Several industrial accidents causing many casualties highlight the potential impact of a terrorist 
attack on chemical storage sites or transport vehicles. In 1984, a methyl isocyanate leak at a Union 
Carbide plant in Bhopal, India, killed as many as 5,000 people and injured more than 14,000 [1]. In the 
United States since 2002, three major chlorine gas leaks have occurred; one due to a ruptured hose, 
another due to the rupture of a tanker in a train accident, and the third due to an industrial fire causing 
several deaths [2]. Explosions in a chemical plant could also disseminate toxic materials into the 
atmosphere and surrounding grounds, thus causing an environmental health emergency. 
The number and variety of different chemicals that pose a health risk to civilian populations is 
daunting. Terrorists could use any of the traditional chemical warfare agents, ranging from nerve gas 
and cyanide to pulmonary and vesicating (blister-causing) agents. Whether we like it or not, we must 
accept the existence of and the risk of chemical warfare agents (CWA) use against the society. The 
world received a shocking reminder of the potential impact of terrorist use of chemical weapons when 
the Aum-Shinrikyo sect synthesized the organophosphate sarin and deployed it against civilian targets 
in Japan 1994 and 1995 [3]. The most serious incident of chemical terrorism until today was the attack 
in the Tokyo subway in 1995 which resulted in 13 fatalities and approximately 5,000 casualties. For 
practical purposes the MASH project developed a number of well defined scenarios [4]. The scenarios 
involve CWA, toxic industrial chemicals (TICs) and radioactive materials and became the standard 
reference cases against which diagnostic needs were discussed. 
Radiological accidents that exemplify the potential impact of a local dispersion of radioactive 
materials also exist. The 1987 Goiânia accident in Brazil took the lives of four persons with acute 
radiation sickness and contaminated several hundred persons. More than 100 persons of the 112,000 
screened were also internally contaminated [5]. In the Goiânia accident, the radiological agent was 
cesium-137 in the form of cesium chloride, a radiological material in the form of a salt that is easily Int. J. Environ. Res. Public Health 2011, 8 
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aerosolized and dispersed which can result in widespread contamination. Other accidents with 
industrial radioactive sources have involved cobalt-60 and iridium-192 in the form of metal, although 
both of them are not that easily dispersed as cesium chloride. 
However, a recent radiological accident in Western Delhi (India) involved unshielded cobalt-60 
source [6] and is a good illustration of the fact that considerable resources must be spent to recover and 
safely dispose these types of highly radioactive materials. The MASH project also developed a number 
of well defined scenarios [4] involving radioactive materials which became the standard reference 
cases against which diagnostic needs were discussed. 
1.2. General Principles for Modern Biotechnology Diagnostics 
The term biotechnology describes practical applications of the life sciences, ranging from medicine 
and agriculture to bio-inspired materials. The biotechnology industry grew very rapidly during the 
1990s. Part of the reason for this rapid growth was the integration of the life sciences with other 
enabling technologies such as computers and analytical chemistry by the pharmaceutical manufacturing 
industry. Due to the announcement in 1999 that the human genome had been sequenced, a new era of 
biotechnology known as “genomics” was ushered into research and development. In this report we 
discuss some prerequisites for the implementation of modern biotechnology diagnostics: 
  Rapid diagnostic tests must be reliable and easily used in mass casualty situations. 
  Immediate as well as long-term effects of exposure to chemicals and radiation must   
be understood. 
1.3. Recent Developments in Biotechnology Diagnostics 
1.3.1. Genomics 
Genomics is a powerful tool to study human genetic variation, which could help identify individual 
resistance and susceptibility to diseases and responsiveness to medical treatment options. The field 
includes intensive efforts to determine the entire DNA sequence of organisms and fine-scale genetic 
mapping efforts. In contrast, the investigation of the roles and functions of single genes is a primary 
focused of molecular biology or genetics and is a common topic of modern medical and biological 
research [7]. 
1.3.2. Transcriptomics 
Transcriptomics is the branch of molecular biology that deals with the study of messenger RNA 
molecules produced in an individual or in a population of a particular cell type. Various methods for 
reducing the likelihood of false positives or negatives, and new computational approaches are 
continually being developed. Computer software is commercially available that can perform many of 
the calculations and data manipulations needed for microarray data analysis [8]. Int. J. Environ. Res. Public Health 2011, 8 
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1.3.3. Proteomics 
Proteomics is the large-scale study of peptides and proteins, particularly their structures and 
functions. During recent years, modern high throughput mass spectrometry (MS) together with 
powerful computational bioinformatics and biostatistics efforts has significantly expanded the 
capability and impact of proteomics. Many biomedical industrial analysts predict that proteomics will 
yield additional practical applications, such as drug targets and biomarkers. Ongoing research and 
development is aimed at further increasing the throughput of proteomics methods [9]. 
1.3.4. Metabolomics/Metabonomics 
Metabolomics is the “systematic study of the unique chemical fingerprints that specific cellular 
processes leave behind”—specifically, the study of their small-molecule metabolite profiles. Since 
metabolites are the products and by-products of many biosynthetic and catabolic pathways, 
metabolomics is now applied to disease diagnosis. Furthermore, it also includes the identification of 
drugs or chemical exposures [7,10]. 
1.3.5. Bioinformatics and Systems Biology 
Bioinformatics is the application of information technology and computer science to the field of 
molecular biology [11]. Common activities in bioinformatics include mapping and analyzing DNA and 
protein sequences, aligning different DNA and protein sequences to compare them and creating and 
viewing 3-D models of protein structures. The primary goal of bioinformatics is to increase our 
understanding of biological processes. 
1.3.6. Biologically-Based Sensors (Biosensors) 
A biosensor is a device for the detection of an analyte that combines a biological component with a 
physicochemical detector component. The fields of application for biosensors include high throughput 
screening of pharmaceuticals and the possibility of portable sensors for chemical or other hazards or 
pathogens [12]. In this paper we discuss the possible use of biotechnology methods for diagnostics 
after an accident with chemical or radiological agents. 
2. Human Biomonitoring 
Biomonitoring is a valuable tool for assessing human exposures to chemical contaminants in the 
environment. Biomonitoring tests can be divided into biomarkers of exposure, effect, and susceptibility. 
In studies of community exposure to an environmental contaminant, biomarkers of exposure are most 
often used. The ideal biomarker should be sensitive, specific, biologically relevant, practical, 
inexpensive, and readily available. Seldom does a biomarker meet all of these criteria, and most 
biomarkers represent a compromise. In designing a community exposure study, consideration should 
also be given to the selection of the test population, the practicality of collecting biological samples, 
temporal or seasonal variations in exposure, the availability of background comparison ranges, and 
interpretation of the test results. Biomonitoring tests provide unequivocal evidence of exposure, but Int. J. Environ. Res. Public Health 2011, 8 
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they do not typically identify the source of exposure. Furthermore, rarely do the test results predict a 
health outcome. For many chemicals, testing must be conducted soon after exposure has occurred. In 
spite of these limitations, the use of biomonitoring is finding wider application in many scientific 
disciplines. Recent advances in analytical techniques are expanding the utility of biomarker testing in 
public health investigations [13]. 
3. Biomarkers 
Biological indicators or biomarkers generally include biochemical, molecular, genetic, immunologic, 
or physiological signals of events in biological systems. The events are depicted as a flow chart 
between an external exposure to a chemical and resulting clinical effects [14].  
The endpoint of biological monitoring is often referred to as a biomarker, defined as “a change 
induced by a contaminant in the biochemical or cellular components of a process, structure or function 
that can be measured in a biological system” [15]. Since biomarkers lie on a flow chart (Figure 2), it 
may be difficult to delineate between biomarkers of exposure and effect [16]. 
Figure 2. Simplified flow chart of classes of biomarkers [17].  
 
3.1. Biomarkers of Exposure 
Biomarkers of exposure have been defined as “a chemical or its metabolite, or the product of an 
interaction between a chemical and some target molecule or cell that is measured in an organism” [18]. 
It has been suggested, that an ideal biomarker of exposure should be “specific for a chemical, 
detectable in small quantities, measured by non-invasive techniques, inexpensive, associated with prior 
exposure and have an excellent positive predictive value to a specific disease status” [19]. Indeed, it is 
a hard task to discover biomarkers of exposure for various toxic chemicals that address all criteria Int. J. Environ. Res. Public Health 2011, 8 
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above. However, many biomarkers have been identified and used in occupational surveys of exposure 
to various chemicals [20]. 
It is generally assumed, that the longer the half-life of a marker, the better it can be correlated with 
effects resulting from chronic, long-term, low-level exposure to cumulative toxicants. When 
investigating possible exposure of toxic compounds, the choice of biomarker should depend on how 
long after suspected exposure the sampling was performed. 
3.1.1. Concentration of Parent Chemical in Blood vs. Urinary Metabolites 
Relevance and stability are perhaps the most important properties making a biomarker suitable for 
field applications. In this respect, the concentration of the parent compound in biological media is 
generally preferable to that of metabolites, which can be shared with other substances. Metabolic 
specificity means that the metabolite is derived exclusively from the parent compound of interest. For 
some metabolites, the specificity is low since large amounts of these metabolites may be derived from 
other sources [21]. 
Therefore, provided that sampling strategies and storage procedures are carefully planned, the 
parent compound is usually better correlated with exposure as compared to its metabolites [22]. 
However, the parent compound usually has a shorter half-life, can be volatile, and is usually unrelated 
to adverse effects, which often occur as a consequence of its biotransformation and metabolic 
activation. If the focus is on dose-response relationships, urinary metabolites have successfully been 
used as suitable biomarkers of dose [23]. 
3.1.2. Adducts to Macromolecules or DNA 
The calculated grade of binding to proteins (such as hemoglobin or albumin) or DNA (usually in 
lymphocytes) is useful as a biomarker, particularly when assessing exposure to genotoxic compounds, 
because it reflects the dose that has avoided detoxification and reached its target protein or DNA [24]. 
Because the life span of red blood cells is comparatively long (approximately 4 months), binding to 
hemoglobin is considered a good biomarker to measure repeated exposure or exposure that occurred 
weeks or even months before sampling [25]. 
Albumin has a shorter life-time in blood (20–25 days) and these adducts will thus reflect more 
recent exposures. One advantage of albumin is that toxic compounds can directly react with this 
protein when reaching the blood without having to penetrate a cell membrane before forming an 
adduct [19]. 
Although macromolecule adducts seem like ideal biomarkers of effect, it should be mentioned that 
adduct measurements are difficult to perform and to standardize, and are limited to compounds or 
metabolites forming adducts. 
3.2. Biomarkers of Effect 
A biomarkers of effect has been defined as “A measurable biochemical, physiologic, behavioral, or 
other alternation in an organism that, depending on the magnitude, can be recognized as associated 
with an established or possible health impairment or disease” [20]. It has been suggested, that ideal Int. J. Environ. Res. Public Health 2011, 8 
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biomarkers of exposure should meet criteria such as non-invasiveness, sensitivity and reflect early 
responses that precedes functional damage. Analytical methods must be reproducible, easy to perform 
and applicable to a large number of samples. 
Biomarkers of effect may be of value in hazard identification and dose-response assessment. In 
hazard identification, biomarkers may facilitate screening and/or identification of a toxic agent and 
characterization of the associated toxicity. 
The lack of validation of most biomarkers of intermediate effect is probably the most common 
argument against broad use of biomarkers in risk assessment. However, efforts to validate biomarkers 
are rapidly generating a large amount of data measuring intermediate effects occurring after exposure 
and before illness. Therefore, they should identify early and reversible biochemical events that may 
also be predictive of later response [23,26]. However, altered physiology is also considered as relevant 
biomarkers of exposure. The further to the right in the flow chart (Figure 2) the biomarker is, the 
greater the clinical or health relevance of its measurement. An abnormal value of a biomarker of effect 
near the centre of the flow chart may not signal negative effects on the health of an individual or group 
if, for example, the cause is reversible and steps are taken to ensure that the exposure that caused it 
ceases [15]. 
Unfortunately, the mechanism of action of many toxic chemicals is unknown at present. 
Furthermore, there are individual variations in the response to equivalent doses of chemicals. While 
the outcome of a chemical insult in an individual may be predicted more accurately from biomarkers 
of effect(s), such biomarkers may not be specific for a single causative agent. Nevertheless, many 
biomarkers of effect are used in everyday practice to assist in clinical diagnosis. Therefore, most 
biomarkers of effect have been identified starting from clinical conditions, extrapolating backward to 
document changes or exposure preceding illness (e.g., early markers of nephrotoxicity that was 
discovered in the clinic). However, clinical alterations can hardly be interpreted in terms of toxicity  
in the absence of experimental models, providing some mechanistic clues. Therefore, numerous 
experimental animal and cellular studies have contributed to the attempts to identify new biomarkers 
of effect. 
Prospective epidemiological studies are also often used for validation of the effect of biomarkers. 
This type of study provides estimates of the risk of disease of individuals using monitoring of 
particular biomarkers. Such a strategy is suitable when the outcome is relatively frequent, and the 
measured biomarker is inexpensive and readily available, e.g., serum cholesterol in cardiovascular 
disease [27]. 
3.3. Biomarkers of Susceptibility 
An individual’s susceptibility to environmentally mediated disease may arise from genetic causes or 
from non-genetic factors such as age, concomitant disease state, diet, or dietary supplementation. 
Genetic polymorphisms may be markers of susceptibility. The rapid advances of the Human 
Genome and Environmental Genome projects are generating a long list of genes and their variants 
(polymorphisms). Research is helping us to understand which genes are perturbed on the pathway to 
disease. Many of these genes are quite general in their function and broadly applicable to the 
assessment of susceptibility. Such genes or groups of genes will, for example, influence or control cell Int. J. Environ. Res. Public Health 2011, 8 
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differentiation, apoptosis, cell cycle kinetics, or DNA repair. Receptor-mediated pathways involving 
alterations in signal transduction can influence a variety of health outcomes. There is a spectrum of 
human genetic variability such that a distribution of responses to a given exposure can sometimes  
be predicted. 
New technologies such as microchip arrays allow researchers to explore patterns of gene expression. 
In the face of this burgeoning information and data being gathered by the National Institutes of Health 
and in other databases, the challenge for researchers interested in environmentally mediated disease or 
risk assessment is to understand the functionality of genetic polymorphisms and to relate this to 
disease. We may gain this understanding in humans, particularly by relating laboratory, clinical, and 
epidemiologic findings. To date, most genetic susceptibility studies have looked at cancers as an end 
point, although research on other diseases such as asthma is beginning to grow. As our understanding 
of functionality grows, so will our need for understanding of the ethical implications of our knowledge 
to individuals and society [15,28,29]. 
Human Biological Monitoring (HBM) has long been used in occupational health as part of a 
preventive strategy in the medical surveillance of workers. Currently it is increasingly used as a tool in 
environmental health policy. More than the classical environmental measurements, pollution gets 
personal [30]. HBM not only provides valuable information on exposure and its possible effects on 
health, but also has great impact in raising awareness for possibilities of prevention, and serves as a 
basis for establishing and evaluating policy measures. 
Besides its strong points, HBM clearly has its limitations, including challenging logistical problems 
and important ethical concerns. Test results are often poorly related to possible health outcomes. They 
provide only a snapshot of substances present in the body at a single point in time and do not provide 
information about the source or history of exposure. A long delay may also exist between the 
availability of test results, the identification of the impact on health and the prospect for measures [30]. 
Therefore, much work needs to be done, in particular with respect to the proper interpretation of HBM 
data and its translation into policy actions. Research should allow for a more appropriate use of HBM 
in the prevention of diseases by further validation of HBM procedures, establishment of relations 
between biological monitoring parameters and early indicators of disease, development of scenarios 
for translation into policy, progress in effect monitoring, and provision of better conditions for HBM 
programs (development of less invasive biomarkers, development of strategies for communication by 
professionals, setting up the appropriate legal conditions, etc.) [31]. 
The future success depends on a twofold approach: thorough evaluation of the biomarkers that have 
been found to be useful in various settings [4] and search for new biomarkers [1]. The former is not 
always easy and hence much attention has been spent on the latter bringing new technologies to bear to 
look for new biomarkers (see Tables 1 and 2). A marker may be good in one clinical setting, but not in 
another. The very best biomarkers will be useful in many contexts. Networks of scientists and 
clinicians should be used to evaluate multiple biomarkers simultaneously. Another very important 
feature of the utility of biomarkers is that they must be easy to analyze rapidly and preferably at the 
bedside if clinical decision-making is to be optimally affected by them.  Int. J. Environ. Res. Public Health 2011, 8 
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Table 1. Example of chemicals, biomarkers of exposure and health effects. 
Chemical Biomarker  Sample  Health  effects 
Nerve Agents 
Red blood cell 
or serum 
cholinesterase 
EEG changes 
Whole blood 
Diffuse muscle cramping, runny nose, difficulty 
breathing, eye pain, dimming of vision, sweating, 
muscle tremors, loss of consciousness, seizures, 
flaccid paralysis. 
Cyanides 
Cyanide or 
thiocyanate 
Blood or urine 
Giddiness, palpations, dizziness, nausea, vomiting, 
headache, eye irritation, increase in rate and depth 
of breathing (hyperventilation), drowsiness, loss of 
consciousness, convulsions and death. 
Vesicants/ 
Blister Agents 
Thiodiglycol Urine 
Burning, itching, red skin, mucosal irritation, 
shortness of breath, nausea and vomiting 
Ricin  Ricinine 
Urine, 
respiratory 
secretions, 
serum, and 
direct tissue 
Nausea, diarrhea, vomiting, fever, abdominal pain, 
chest tightness, coughing, weakness, nausea, fever 
Benzene 
Benzene, 
Phenol 
Blood, exhaled 
air, urine 
Confusion, sleepiness, rapid pulse, loss of 
consciousness, anemia, damage to the nervous 
system, suppression of the immune system, 
carcinogenic, death 
Carbon 
monoxide (CO) 
Hematologic 
biomarkers of 
coagulation 
and 
inflammation. 
Blood 
Tissue hypoxia, headache, nausea, vomiting, 
dizziness, blurred vision, cardiac arrhythmias, 
myocardial ischemia, cardiac arrest, hypotension, 
respiratory arrest, noncardiogenic pulmonary 
edema, seizures, and coma. 
Nitrogen 
dioxide 
Nitrate, 
pentane 
Urine, breath  Wheezing, coughing, colds, flu and bronchitis 
Sulfur dioxide  S-sulfonate  Blood  Lung function changes, life-threatening 
Polycyclic 
aromatic 
hydrocarbons 
(PAHs) 
PAH 
metabolites 
Urine 
Pulmonary, gastrointestinal, renal, and dermatologic 
systems, carcinogenic 
Organic Gases 
(Volatile 
Organic 
Compounds—
VOCs) 
VOC’s or 
metabolites 
Breath, blood, 
urine 
Allergic sensitization or asthmatic symptoms, 
carcinogenic 
 Int. J. Environ. Res. Public Health 2011, 8 
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Table 2. Examples of radiation biomarker assays and exposure assessment methods. 
Assay 
Dose 
range 
(Gy) 
Specificity 
Induction 
time 
Persistence 
Speed of 
analysis 
Field 
amenable 
Automation 
potential 
Dicentric 
Assay 
0.2–5 High Hours 
Several 
months 
2+ days  No  Partial 
FISH  0.5–5 Moderate Hours  Years 3+  days No  Partial 
MN Assay  0.3–5 Mod.–low Hours 
Several 
months 
3+ days,  No  Yes 
PCC Assay  ND–20+ High–mod.  Hours 
Several 
months 
2+ days  No  Partial 
Gene 
markers 
Variable, 
~0.2–5 
Low 
Variable 
Hours–
days 
Variable 
Hours—days 
<1 day  Possible  Possible 
Protein 
markers 
Variable, 
~0.5–20+ 
Low 
Variable 
Hours–
days 
Variable 
Hours—days 
<1 day  Possible  Possible 
Blood cell 
kinetics 
1–10  Low  Immediate  Up to 2 weeks  Days  Yes  Yes 
Bioassay *  <0.001 High  NA  Variable <1  day  No  Yes 
* Bioassay refers to analyzing radionuclides from internal contamination in biological materials and estimation of resulting 
absorbed dose. ND indicates that a value has not been determined and NA is not applicable. 
4. Chemical Exposure and Effects on Specific Organs 
4.1. Chemicals Affecting the Respiratory Tract 
Many toxic chemicals can damage the respiratory airways, with potentially life-threatening effects. 
Ammonia, various alkalis (e.g., bleach and sodium hydroxide), hydrochloric and sulfuric acid, 
vesicants (e.g., sulfur mustard) and other corrosive agents affect the upper airways, the portion of the 
respiratory tract that begins at the mouth and nose and ends at the larynx (voice box). Inhalation of 
these chemicals can cause acute inflammation, painful ulcerations, increased secretions, and 
difficulties in breathing and swallowing. Secondary bacterial infections may further exacerbate the 
initial injury. Damage to the upper airway can lead to respiratory failure and death. Exposure can also 
lead to long-term health problems. For example, chronic respiratory problems, such as scarring and 
narrowing of the trachea, have been observed in Iranians exposed to sulfur mustard during the   
Iran-Iraq War of the 1980s (vesicating chemicals will be discussed in more detail in the section entitled 
“Chemicals Affecting the Skin, Eyes, and Mucous Membranes”). 
Some industrial chemicals, including ammonia, chlorine, phosgene, and per-fluoro-isobutylene 
(PFIB) can cause lower respiratory tract injuries, particularly life-threatening pulmonary edema. 
Pulmonary edema—the leakage of fluid into the lungs—prevents oxygen delivery to the blood, 
ultimately preventing oxygen from reaching the brain, kidneys, and other organs. Symptoms may be 
immediate or delayed; chlorine causes immediate airway irritation and pain, whereas phosgene 
exposure may not be evident for 24 to 48 hours [32]. People who survive a single, acute exposure to 
respiratory airway toxicants generally show little or no long-term health problems, although some may Int. J. Environ. Res. Public Health 2011, 8 
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eventually develop asthma or chronic bronchitis. Individuals at greatest risk are those with pre-existing 
heart or lung disease. 
4.1.1. Diagnostic Tools 
Current diagnostic capabilities are limited. Exposure to chlorine, phosgene, or any of the major 
alkalis is determined based on clinical signs and symptoms. No screening tests are available to identify 
individuals exposed to low levels of chemicals. 
Mechanistic studies may also aid in the development of new diagnostic approaches. Some 
chemicals generate metabolic byproducts that could be used for diagnosis, but detection of these 
byproducts may not be possible until many hours after initial exposure. Additional research needs to be 
directed at developing sensitive and specific tests to identify individuals quickly after they have been 
exposed to varying levels of chemicals toxic to the respiratory tract. 
One way to approach the diagnostic problems is by development of lung-specific biomarkers. When 
the integrity of the lung epithelium is broken, lung-specific proteins may leak into the blood 
circulation. The appearance of such proteins in peripheral blood may indicate lung injury. Clara cell 
protein 16 and lung surfactant D are two proteins that are produced predominantly in the lungs and 
therefore have been proposed as biomarkers of public health lung diseases. 
Clara cell protein 16 (CC16) is a protein which is secreted in large amounts at the surface of 
airways from where it leaks into the serum, most likely by passive diffusion. It acts as an 
immunosuppressant and provides protection against oxidative stress and carcinogenesis. The serum 
concentration of CC16 is a new sensitive marker to detect an increased permeability of the epithelial 
barrier, which is one of the earliest signs of lung injury. It has been detected in a variety of both 
clinical and experimental situations such as exposure to smoke, chlorine, lipopolysaccharides and 
ozone and is indeed a promising biomarker for this area of research. It is important though to consider 
that serum levels of CC16 are not specific to one agent, disease state or exposure—it is merely an 
indication of lung injury [33]. 
Surface protein D (SPD) is a large, multimeric protein produced mainly by cells of the lungs.  
It plays an important role in innate immunity and in host defense responses. Over-expression of SPD 
has been associated with chronic inflammatory conditions such as asthma and interstitial pulmonary 
fibrosis and chronic obstructive pulmonary disease (COPD) [34]. 
When exposed to chemical agents it is very likely that the lungs are affected. Inhalation of toxic 
substances can cause serious injuries both in the acute phase but can also cause chronic damages. It is 
therefore very important to quickly be able to evaluate the severity of the damage in order to treat it 
correctly. Common markers for inflammation are cytokines in lung tissue, lavage fluid or serum. By a 
simple blood sample it is possible to run an assay (ELISA or Bioplex) which gives information on 
which cytokine levels that are elevated and the inflammation can be treated and monitored over time. 
The collection of exhaled breath condensate (EBC) is a simple and non-invasive technique to 
measure mediators of airway inflammation. It is portable which makes it good for field studies [35].  
In EBC exhaled and cooled aerosol droplets serve as seeds for condensation resulting in liquid phase 
accumulation. EBC does not affect the airway in contrast to bronchial biopsy, bronchoalveolar lavage 
and induced sputum. There are two groups if inflammatory biomarkers in EBC which are of most Int. J. Environ. Res. Public Health 2011, 8 
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importance; eicosanoids and cytokines. Eicosanoids, such as 8-isoprotane, are formed by lipid 
peroxidation of arachidonic acid during oxidative stress. Cytokines are small proteins involved in 
mediating inflammation and tissue repair. Cytokine concentrations in EBC samples are usually 
quantified by enzyme-linked immunosorbent assay (ELISA). 
One of the current limitations of EBC measurements is the low concentration of many biomarkers 
which makes it difficult to perform measurements. It is likely that even more sensitive assays will be 
able as more potent antibodies are developed and new molecular techniques are introduced [36]. 
Proteomics, which applies high resolution gel electrophoresis or mass spectrometry (MS) to detect 
multiple proteins in biological samples, may also be useful to analyze the proteins in EBC. 
Exhaled nitric oxide (eNO) is a reliable marker of airway inflammation. The measurement is easy to 
perform and the result is immediately available. Increased levels of eNO have been measured in 
patients with respiratory diseases such as asthma and COPD. Therefore it is believed that eNO could 
be used as a noninvasive biomarker of respiratory inflammation [37]. It is particularly attractive 
because the test requires little effort from the patient, can be measured even in young children and the 
result of the test can be immediately available. 
4.2. Chemicals Affecting the Skin, Eyes and Mucous Membranes 
Vesicating agents such as sulfur mustard, nitrogen mustard, lewisite, and caustic industrial 
chemicals can cause severe blistering and burns to the eyes, mucous membranes, skin, and upper 
airways, as well as chronic eye inflammation and blindness. The eyes are the organs most sensitive to 
these chemicals. Vesicants may also affect other parts of the body, including the respiratory tract, 
immune system, and bone marrow. Sulfur mustard can cause tissue damage within minutes of exposure. 
Physical injury from other vesicating agents may not be evident for several hours and may result in 
delayed recognition of exposure [38]. In such situations, an exposed individual may put others at risk 
of secondary contamination. 
The immediate symptoms of exposure to one of these chemicals includes: coughing followed by 
difficulty breathing/shortness of breath and possibly fluid in lungs within 2–6 hours; burning sensation 
in the throat and eyes accompanied with watery eyes and blurred vision; nausea and vomiting and 
developing skin lesions. 
The exposure may cause delayed effects even if the person has no clinical symptoms. These 
includes: difficulty with breathing and shortness of breath and coughing up white to pink-tinged fluid; 
low blood pressure; heart failure and chronic bronchitis. 
4.2.1. Diagnostic Tools 
At this time, diagnosis of vesicant injury is based on clinical signs and symptoms and the detection 
of specific agents in the environment. There are no clinical laboratory tests for sulfur mustard in blood 
or tissue. However, compounds such as thiodiglycol (TDG) are produced in the body after exposure to 
sulfur mustard and can be detected in blood, urine, and tissue. Analysis of these compounds requires 
the use of complex technologies such as gas chromatography-mass spectrometry. Int. J. Environ. Res. Public Health 2011, 8 
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4.3. Chemicals Affecting the Nervous System 
A variety of chemicals are known to affect the nervous system. Some directly target neural 
signaling pathways. These include the classic nerve agents (e.g., sarin, soman, tabun, and VX) [39]; 
organophosphate pesticides [40] and some animal toxins (e.g., botulinum toxin). Chemicals can also 
affect the nervous system indirectly. For example, metabolic poisons (e.g., cyanide) disrupt cellular 
respiration, which ultimately prevents the brain from getting sufficient oxygen and energy. Some 
vesicating agents (e.g., sulfur mustard) appear to have neurological effects as well, although the 
specific mechanism by which they affect the nervous system is poorly understood. 
Neurological symptoms depend on the type of chemical, the level of exposure, and the time elapsed 
following exposure. Exposure to nerve agents, metabolic poisons, or high levels of sulfur mustard can 
trigger seizures and loss of consciousness. Other acute effects of nerve agent poisoning include muscle 
paralysis, cardio respiratory depression, and massive secretion from mucous membranes, eye irritation 
(miosis), and blurry or dim vision. Other acute effects of exposure to high doses of sulfur mustard 
include behavioral effects and cognitive difficulties. Nerve agents and metabolic poisons also appear to 
have serious long-term neurological effects, including neuronal degeneration, but these have not been 
studied extensively. 
The physical states of chemicals that affect the nervous system are an important determinant of the 
requirements for developing effective countermeasures. Although some chemicals that affect the 
nervous system exist primarily in the form of a vapor (e.g., hydrogen cyanide), others are oily liquids 
that are very difficult to remove from the environment and extremely toxic even at miniscule levels 
(e.g., VX). For these persistent agents, it would be ideal to have pretreatments with long-lasting 
protective effects that can be administered in advance of possible exposure to personnel who must 
enter contaminated sites. 
4.3.1. Diagnostic Tools  
Diagnosis following an acute exposure to a nerve agent is generally based on clinical observations 
of specific symptoms. Environmental sensors may provide valuable information on probable chemical 
exposure. One of the greatest challenges in diagnosis is determining whether an individual exposed to 
a nerve agent is experiencing chemically induced seizure activity in the absence of visible convulsions, 
since the chemicals that trigger seizures may also cause unconsciousness or paralysis. Sustained 
seizure activity that is uncontrolled can result in permanent brain injury and death. The standard test 
for seizure activity involves placing electrodes on the scalp to record electrical activity in the brain 
using electroencephalography (EEG). Such devices are not portable and have limited practical value in 
evaluating patients in a mass casualty situation. 
4.4. Example of Future Diagnostic Tools 
4.4.1. Saliva as Diagnostic Tools for Chemical Exposure 
Evaluation of saliva can yield information on chemical exposure. Interest in saliva as a diagnostic 
medium has increased dramatically during the last decade, as saliva and other oral fluids have been Int. J. Environ. Res. Public Health 2011, 8 
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shown to reflect systemic fluid levels of therapeutic, hormonal, immunological and toxicological 
molecules. Oral fluids have also been shown to contain biomarkers associated with infectious and 
neoplastic diseases. Similarly, the analysis of salivary fluids, like blood-based assays, yields useful 
diagnostic information for the assessment and monitoring of systemic health and disease states, 
exposure to environmental, occupational, and abusive substances, as well as for the early identification 
of harmful agents. 
Using sophisticated mass spectrometry equipment, researchers have been able to identify 
breakdown products of a common pesticide in the saliva of rats exposed to known amounts of the 
pesticide. The researchers are working now to develop a simpler, portable microanalytical sensor 
system to quickly diagnose pesticide exposure in humans and a modeling method than can estimate the 
dose. Researchers say the technology could be adapted to test for a variety of contaminants, including 
chemical warfare agents. Researchers believe saliva monitoring may be able to detect a broad range of 
chemical contaminants from ongoing occupational exposure, accidents or even acts of war and 
terrorism [41]. 
The need for further research in salivary diagnostics, and advocate that oral fluid-based diagnostics 
have the potential to provide more accurate and less expensive diagnostic procedures than current 
methodologies available [42,43]. 
5. Radiation Exposure and Health Effects 
Nuclear and radiological scenarios can result in several different types of radiation exposures that 
range from external exposure to penetrating radiation (such as - and x-ray sources) to exposure from 
internalized radionuclides. The primary concern from α-emitting radionuclides is internal contamination 
since the range of the α-particle is very short and cannot penetrate the dead layer of the skin but can 
deliver a significant dose to tissues in the body if internalized. The range of β-particles is longer and 
dependent on the energy of the emission. If deposited on the skin, radiations burns can result from the 
energy deposited and absorbed in the skin and β-emitting radionuclides pose a significant health 
hazard if internalized. The impact of - or x-ray emitting nuclides, or penetrating radiation, depend on 
the activity of the source. High activity sources can result in cutaneous effects, which are often 
localized. Some dose can be received from internalized -emmitting nuclides, however, the primary 
concern in most scenarios is from high doses received externally. 
5.1. Radiation Injury 
A whole body, or significant partial body, external exposure to penetrating radiation (>1 Gy) 
delivered in a short time from, i.e., at a high dose rate, will result in specific signs and symptoms 
termed acute radiation syndrome (ARS) [44]. The four phases of ARS include prodromal, latent, 
manifest, and recovery or death. The prodromal phase occurs in the first 48 hours and occasionally up 
to 6 days. The latent phase is characterized by a short, transient period of time (few days to a few 
weeks) where patients demonstrate some recovery by being less affected by symptoms. Manifest 
illness then follows which may continue for several weeks, and is dominated by immunosuppression. 
The final phase will be recovery or death, dependent on the dose and other factors such as the 
individual’s age, existence of other injuries, etc. Int. J. Environ. Res. Public Health 2011, 8 
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The focus of this discussion is primarily on acute, high dose exposures from external sources and 
the acute effects observed after such exposures. However, it is important to note that other injuries and 
latent effects can occur from radiation exposure. In the case of internalized radionuclides, specific 
organ damage can occur to any organ in which the radionuclide accumulates in or is retained in. For 
example, α-emitting, insoluble plutonium and americium radionuclides can be retained in the lungs for 
a long time after inhalation exposure. Once incorporated into the body, they accumulate in the bone. 
Therefore, these nuclides can significantly impact pulmonary tissue, resulting pneumonitis or fibrosis, 
and the red bone marrow resulting in impaired hematopoietic function. Latent effects that can result 
from radiation exposures include cataract formation and increased cancer risk. 
5.2. Organ System Effects 
Specific symptoms, their onset and severity are highly dependent on absorbed radiation dose. 
Proliferating cells are most sensitive to radiation and hence exhibit acute effects. As such, 
hematopoietic stem cells and intestinal crypt cells are inherently sensitive and result in clinical effects 
that predominate in a predictable range of doses [45]. The specific syndromes manifested in ARS 
include the neuro/cerebrovascular, hematopoietic, gastrointestinal, and cutaneous systems. 
The neurovascular or cerebrovascular system will exhibit symptoms, the degree of which varies 
depending on the dose received. In fact, the onset of nausea and vomiting has been used to estimate 
dose and is well correlated. Fatigue, fever, headache, hypotension, as well as neurological and 
cognitive deficits can be observed [46]. At very high doses (≥30 Gy), cerebrovascular syndrome 
occurs. Immediate nausea, vomiting, hypotension, ataxia, and convulsions may occur soon after 
exposure, followed by unconsciousness and death within days [47]. The origin of some of these 
symptoms relate to changes in permeability in the blood brain barrier and vasculature system. 
Symptoms observed in from the gastrointestinal system include diarrhea, abdominal cramps, and 
pain resulting from losses in the mucosal layer in the gut. Gastrointestinal syndrome occurs with doses 
in the range of 6–20 Gy due to death of the intestinal stem cells causing hemorrhaging. In this dose range, 
prompt onset of nausea, vomiting, and diarrhea will be observed followed by recurrence of gastrointestinal 
symptoms after the latent phase. Sepsis can occur from gut flora leaking into the systemic circulation. 
Intestinal bleeding, electrolyte imbalance, and death may follow, usually in 8–10 days. 
The hematopoietic system will exhibit in general an initial rise in some cells, followed by a decline. 
Lymphocytes, granulocytes, and thrombocytes are all affected. The depletion of neutrophils will result 
in increased susceptibility to infection while thrombocyte depletion can result in hemorrhaging. 
Hematopoietic syndrome occurs at whole body doses of 2–10 Gy due to bone marrow depression and 
is most strikingly characterized by lymphocyte depletion. Blood cell depletion kinetics can be used to 
indicate dose and facilitate prognosis. Many persons can survive ARS if treated with fluids, antibiotics, 
and blood products. If standard care is performed, death generally results only when there are no 
surviving stem cells in the red bone marrow. 
The cutaneous system also exhibits effects after radiation exposure [48]. Onset and degree of 
erythema and epilation has been correlated with radiation dose. At very high doses, swelling, blistering, 
and desquamation can occur. While cutaneous syndrome is not generally a stand-alone mechanism of 
mortality, it contributes the overall systemic response to radiation and has been implicated in Int. J. Environ. Res. Public Health 2011, 8 
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contributing to multi-organ failure [49]. Furthermore, radiation burns from localized radiation deposition 
on the skin significantly contributed to the observed mortality in Chernobyl victims. 
With successful treatment of high dose radiation exposure and ARS, late effects may be observed in 
other organs. For example, the lungs and kidneys exhibit damage months after the exposure due to 
chronic inflammation leading to fibrosis or necrosis. Some cases can result in multi-organ dysfunction 
and failure. 
5.3. Diagnosis and Assessment 
The appropriate treatment of radiation injury is highly dependent on accurate diagnosis and 
assessment. Current methods used for determining radiation dose include any physical dose estimates 
or reconstruction of the exposure, clinical signs and symptoms, blood cell kinetics, and cytogenetic 
biodosimetry. A simple system for using the collective diagnostic information to rapidly and reliably 
classify acute radiation injury for managing treatment, termed Radiation Injury Severity Classification 
(RISC), has been described [50]. The system was adapted from previously described injury groups [51] 
to address special concerns in management of mass casualty events. A similar approach for medical 
radiation assessment and management which extensively describes diagnostic approaches based on 
organ specific parameters has been developed as part of an EU project termed METREPOL (Medical 
Treatment Protocols for Radiation Accident Victims) [46]. 
Radiation assessment is only one part of the overall decision for treatment of an individual. 
Subsequently, all available knowledge concerning the affected persons(s) such as the existence of 
other injuries, age, health status, and dose will be used in determining eventual treatment and therapy. 
5.3.1. Signs and Symptoms 
The onset of clinical signs and symptoms can be reliably used to assess the extent of radiation dose 
(see Table 3). Some of the symptoms expected after significant radiation exposure (>1 Gy) include 
headache, nausea, vomiting, and diarrhea. At very high whole body or local skin doses (>6 Gy), 
cutaneous effects such as erythema can be observed, as well as seizures and incapacitation above 10 
Gy. Of these symptoms, the most useful and reproducible parameter for assessing dose is the time to 
emesis or vomiting. A very high dose is assessed with onset of these symptoms within one hour, and 
significant dose with onset within 2–4 hours. However, the exact time of exposure must be known in 
order to accurately determine the lapse time before onset. In accident scenarios and in the presence of 
other significant injuries, onset of vomiting may be influenced by shock and trauma. In this case, a 
reliable dose estimate may not be possible based on this parameter. The following assessments are 
primarily valid for whole body doses [45,52,53]. Int. J. Environ. Res. Public Health 2011, 8 
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Table 3. Signs and symptoms correlated with absorbed radiation dose [54]. 
  Onset of Symptom   
ARS/ Dose  Vomiting  Diarrhea  Headache Consciousness  Medical  care 
Mild (1–2 Gy)  >2 hr  -  Slight  -  Outpatient 
Mod. (2–4 Gy)  1–2 hr  -  Mild  -  Hospital 
Severe (4–6 Gy)  <1 hr  Mild, 3–8 hr  Mod., >24hr  -  Special hosp. 
Very sev.  
(6–8 Gy) 
<30 min  Heavy, 1–3 hr  Severe, 3–4 hr  Possible 
Specialized 
hospital 
Lethal (>8 Gy)  <10 min  Heavy, <1 hr    Sec.–minutes  Palliative care 
5.3.2. Blood Cell Kinetics 
Since the hematopoietic system is one of the more sensitive organs to radiation, blood cells 
parameters can be valuable tools in estimating dose. However, the methods discussed again apply 
primarily to whole body exposures and assessments will not be valid for partial body exposures [55]. 
These endpoints are further limited by the natural variability in individual baseline cell counts   
and sensitivities. 
If initiated early, serial blood cell counts can provide a reasonable estimate of dose as well as an 
indication of the treatments needed and eventual prognosis. A specific pattern of blood cell changes 
may be observed in the first couple of weeks after exposure and can help to provide a clear picture of 
the hematological response [56]. These changes involve decreases and increases in granulocytes, 
platelets, and lymphocytes. Granulocytes may transiently rise before neutropenia (severe decrease of 
neutrophilic granulocytes) begins [44]. In some cases, granulocytes may experience an abortive rise 
around day 5–10, which is indicative of residual, viable hematopoietic tissue capable of reproducing 
granulocytes. Lymphocytes decline rapidly and later repopulate if the radiation dose is not too extreme 
where bone marrow or stem cell transplantation is warranted. Platelets may have an initial shoulder 
before decline or begin a progressive decline within the first week depending on dose [57]. 
The parameter most often used and recommended for aiding dose estimation is the kinetics of 
lymphocyte depletion. In the best case, complete blood cell counts with determination of the leukocyte 
differential are obtained immediately and followed up 2–3 times per day over the first week [45]. The 
rate of the lymphocyte decline is highly dependent upon the radiation dose received and can be used to 
estimate exposure based on the slope obtained from the differential counts. Ideally, blood cell counts 
are followed until the nadir in the neutrophil count is established. In assessment of blood cell kinetics, 
some researchers recommend considering both lymphocyte and neutrophil counts or their ratio as an 
indicator of dose [50]. 
Utilization of additional hematological information (i.e., granulocyte, lymphocyte, and platelet 
counts) affords a better diagnosis and facilitates prognosis since the changes observed indicate the 
effect on the blood stem cell pool which can aid the prediction of eventual recovery or existence of 
irreversible injury [57]. If irreversible injury has occurred, definitive care such as stem cell 
replacement is warranted if other injuries are minimal and the dose is not too great. Int. J. Environ. Res. Public Health 2011, 8 
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5.3.3. Biodosimetry 
The most established method used as a radiation biological dosimeter is cytogenetic analysis of 
chromosomal aberrations by the measure of dicentric aberrations in metaphases from blood 
lymphocytes (see Table 4).  
Table 4. Dicentric chromosomes frequency expected in human lymphocytes resulting from 
different radiation doses [45]. 
Dose Estimate 
Dicentrics in peripheral blood lymphocytes 
Per 50 cells (triage)  Per 1000 cells 
0 0.05–0.1  1–2 
1 4  88 
2 12  234 
3 22  439 
4 35  703 
5 51  1024 
The dicentric assay is currently the gold standard in biodosimetry [58]. A blood sample should be 
obtained at least 24 hours after exposure, followed by lymphocyte cell culture, and subsequent 
analysis. The time from sample acquisition to dose estimate is typically 2–3 days. If the radiation event 
involves a large number of individuals, analysis on a triage basis may be performed. This method 
evaluates fewer cells in the analysis to provide a more general estimate of dose category. The dicentric 
frequency observed in the patient is standardized by an in vitro dose-response curve specific for 
different types of radiation. The frequency of dicentric aberrations is well correlated with dose and 
may be used to prepare a dose estimate. Over-dispersion of aberration frequency can be used to 
provide an estimate of partial body dose with the use of mathematical models. However, for certain 
inhomogeneous exposure events, cytogenetic dosimetry is ineffective. Examples of such situations are 
exposure to β-emitting radionuclides deposition on the skin and incorporation of many radionuclides 
that accumulate in specific organs and tissues. Altough internalized caesium-137 has more or less 
uniform distribution in the body and may be an exeption [6,59]. 
The dicentric assay is reliable only up to 5 Gy due to cell death and saturation of the dose response 
curve at higher doses [60]. Another cytogenetic assay using chemical phosphatase inhibitors to induce 
premature chromosome condensation (PCC) has been applied reliably at doses up to 20 Gy [61], the 
utility of which was demonstrated during the Tokai-mura criticality accident [62] and provides a good 
alternative for evaluation of higher doses of radiation exposure. The PCC assay can provide valuable 
complementary information for medical treatment decisions since with present advances in modern 
medicine, the critical decisions concerning definitive care in acute radiation injury is in the dose range 
above 5 Gy. 
Other cytogenetic methods include the micronucleus assay and analysis of stable translocations by 
fluorescence in situ hybridization (FISH). Micronuclei are formed when chromosomes fail to segregate 
properly at mitosis and appear in the cytoplasm. The method requires a longer incubation time than the 
dicentric assay but requires less analysis time because the cells are easier to evaluate. At low doses, the 
micronucleus method is uncertain, since micronuclei also are produced by other clastogens resulting in Int. J. Environ. Res. Public Health 2011, 8 
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a higher background frequency. Additionally, coalescence may occur at high doses causing a flattening 
of the dose-response curve [63]. Fluorescence in situ hybridization (FISH) has been developed for 
retrospective analyses to complement the shorter halflife dicentrics in the lymphocyte pool. FISH 
proved efficacious in detecting stable translocations between chromosomes [64]. Persistent 
translocations may provide a retrospective estimate of stem cell dose many years later [65]. Its value 
has been demonstrated when significant time has elapsed between radiation exposure and the discovery 
of that exposure [54,66,67]. 
5.3.4. Dose Reconstruction 
In many cases, physical dose estimates are not available or will be only a rough estimate for a single 
individual involved in a large accident. However, when available and when time allows, physical dose 
reconstruction of dose may be very valuable since eventual prognosis concerning whole body radiation 
exposure is highly associated with the absorbed dose estimate. In some cases, dose reconstruction 
methods can be applied to estimate the partial body equivalent dose when partial body exposures have 
occurred or in cases where part of the body has been shielded. This greatly facilitates medical 
management decisions since shielding of the lung or essential parts of the bone marrow will greatly 
impact the chance of survival for an exposed individual. 
5.3.5. Future Diagnostics 
Unfortunately, the methods described above are inadequate for the diagnostic evaluation of 
radiation exposure in a mass casualty scenario. None of the methods are suitably fast, high-throughput, 
or field amenable for use in the field for triage sorting and application for making emergency care 
decisions. However, several methods currently under development may be able to address this gap. 
The H2AX foci analysis is based on measurement of a histone-related protein that forms a variant 
form of H2A, which codes the DNA [68]. Double strand breaks in the DNA caused by ionizing 
radiation results in phosphorylation of H2AX adjacent to the number of double strand breaks [69]. 
Antibodies specific fluorescent staining of the phosphorylated form of H2AX, termed γH2AX foci, 
allows observation and quantification of DNA damage. There is a good relation between γH2AX foci 
and DNA damage up to ~5 Gy. Currently, γH2AX foci are counted manually by microscopic analysis, 
but efforts are underway to develop high throughput analyses, potentially using flow cytometry and 
other means. 
Gene expression signatures are also a potential alternative for radiation dose assessment. Microarrays 
embedded on chips for genomic profiling may afford a potentially fast and high-throughput technique. 
This procedure monitors the gene expression profile of cells that can detect 2–3 fold changes in gene 
expression between samples. The specific genes which expression changes following radiation 
exposure have been identified. Recent work suggests that the technique has potential applicability for 
dosimetry estimations [70-74]. A linear dose-response for induction of several genes has been 
observed as low as 0.02 Gy. In a recent study on human peripheral blood from healthy donors, a  
74-gene signature was identified that distinguishes between radiation doses (0.5–8 Gy) and control. 
Expression patterns of five genes (CDKN1A, FDXR, SESN1, BBC3 and PHPT1) from this signature 
were also confirmed by real-time PCR. The authors were able to on a single set of genes, predict Int. J. Environ. Res. Public Health 2011, 8 
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radiation dose at both 6 and 24 hours after exposure without the need for pre-exposure sample, which 
is an important advance for gene expression biodosimetry. The separation by exposure dose was 
clearest between the lower doses with some overlap evident between the highest doses of 5 and 8 Gy. 
An effect of time since the radiation was also evident in the 74-gene signature. Inter-individual 
variation is another important concern for the development of gene expression biomarkers. Within a 
set of ten donors used by Amundsen et al, variations by radiation exposure dose were greater than the 
variations in expression between donors, allowing relative accurate classification of samples by dose. 
In a recent study of radiation induced gene expression in human peripheral lymphocytes using   
real-time PCR, there was a minimal variance of base line expression and consistent radiation responses 
among five genes between 20 healthy donors [75]. Gene expression signatures are looking increasingly 
attractive as potential biodosimeters for radiation exposure. However, further validation in terms of  
in vivo responses in cancer patients and animal models, inter-individual variability, radiation specificity 
of the signatures is still needed. In order to make gene expression signatures practically useful for mass 
casualty screening, they will also be needed to be exported from the laboratory-based microarray 
platforms currently used for discovery research to higher throughput forward deployable platforms. 
Approaches have been suggested based on q-RT-PCR [76] and nano-technology “lab-on-a-chip” 
designs [77]. 
Similar to gene expression profiling, proteomic and metabolomic profiling also hold promise as 
alternative methods for radiation dose assessment. To exploit current advances in the ability to monitor 
changes in protein expression to identify a biomarker radiation exposure, it is necessary to quantify the 
protein expression changes and relate them to dose or establish dose-dependent panel of such changes. 
A number of techniques are available to examine protein profiles including higher resolution   
surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF MS), [78]. 
The approach has been tested in cancer patients before and during radiotherapy and the exposed 
population could be distinguished from the unexposed population with high sensitivity and specificity. 
In the analyses 23 protein fragments/peptides were uniquely detected in the exposed group. This shows 
that the protein profile in serum changes following radiation exposure in a manner that is probably 
dose-dependent. The approach requires further development and a defined dose-response relationship 
remains to be determined. Identification of radiation-induced metabolic changes and an understanding 
of the signaling pathways involved are necessary for development of a reliable metabolomic marker to 
assess radiation exposure and extent of injury. Using state-of-the-art HPLC MS (TOF), the entire 
human metabolome has been illustrated as a feasible compartment to analyse the metabolome with 
respect to radiation dose. 
5.4. Triage 
An initial assessment is required to establish the necessary treatment protocol for injured patients 
involving radiation. Triage is performed so that patients may be sorted according to the urgency of care 
required. In mass casualty situations, patients are further sorted to optimally match patient needs to 
limited resources. Int. J. Environ. Res. Public Health 2011, 8 
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5.4.1. Radiation Independently 
When radiation injury is encountered without other types of wounds, triage is focused on diagnosis 
and establishment of dose estimate. If any internal radiation contamination exists, decontamination and 
decorporation treatment should begin as early as possible since some nuclides can become lodged  
in tissues. The specific therapies for patients after a radiological accident are highly dependent on the 
dose and overall patient assessment. However, in general, the hematopoietic syndrome and resulting  
immune-suppression are the immediate priorities in treatment of radiation-only injuries. Treatment of 
hematopoietic syndrome involves predominately administration of fluids and antibiotics. The use of 
cytokines to stimulate hematopoietic cell proliferation has been proposed but must be initiated within 
the first 24–48 hours to be effective. At higher doses gastrointestinal effects can be observed but few 
treatment options exist for these effects. The final dose cut-off for effective treatment is in the dose 
range where eventual fibrosis of the lung will evolve (~10 Gy). 
5.4.2. Combined with Trauma and/or Wounds 
In many scenarios, radiation injury will be accompanied by burns, wounds, and trauma resulting 
from a blast. During the triage stage, all life threatening injuries should be prioritized and handled first. 
If a contamination is an issue after a patient is stabilized, decontamination and decorporation therapy 
can be considered. Thereafter, burns and wounds should be prioritized. If surgery is required, this should 
take place in the first two days after exposure. Establishment of radiation dose during this period will 
indicate the need for other measures such as supportive care and in some cases isolation. The prognosis 
of irradiated patients with combined injuries is much poorer than those with radiation alone. The 
changes in the traditional triage classification when combined with radiation are shown in Table 5. 
Table 5. Triage categories for combined injuries dependent on radiation dose [45]. 
Conventional triage 
category 
Changes in triage category with whole body radiation 
<1.5 Gy  1.5–4.5 Gy  >4.5 Gy 
Delayed Delayed Variable  Expectant 
Immediate Immediate Immediate Expectant 
Minimal Minimal Minimal Minimal 
Expectant Expectant Expectant Expectant 
Absent Ambulatory  monitoring 
5.5. Emergency Care 
After an initial triage, patients should be sorted into treatment categories with patients having 
exposures less than 1 Gy not normally requiring further treatment and those with greater than 10 Gy 
receiving supportive and palliative care since fatal outcome is anticipated. In general, this stage of care 
is for patients that have received significant but non-lethal doses of radiation. Treatment actions in this 
phase generally address the symptoms resulting from hematopoietic syndrome. Int. J. Environ. Res. Public Health 2011, 8 
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5.5.1. Diagnostic Tools  
Normally the presence of a contaminating radionuclide (a gamma and/or beta emitter) would be 
quickly identified, using portable radionuclide detectors handled by radiation safety officers. 
Individuals with observed external contamination would be quickly decontaminated by removal of 
clothes and washing. Internal contamination as assessed by portable detectors or whole body counting. 
Patient samples would be taken for urgent gamma spectrometry analysis at specialized laboratories 
(responses within hours to days). Selection of individuals for monitoring, including clinical follow-up 
and biological dosimetry, would be considered primarily for patients showing clinical symptoms 
indicative of “acute radiation syndrome”. Responses to “classical” biodosimetry with dicentrics   
would take days to weeks. Dose action levels (upper and lower) regarding internal contamination 
would be considered, evaluating whether to initiate medical treatment to reduce doses (e.g., through 
reduced decorporation by decreased absorption and/or increased excretion; drugs like ferric 
ferrocyanide—“Prussian blue”). 
For individuals exposed to a sealed source of ionizing radiation, i.e., no contamination exists.there 
is a need for extensive biological dosimetry involving accredited and novel methods (see above) 
combined with repeated clinical assessments, particularly of individuals presenting with the “acute 
radiation syndrome”. Both cases illustrate the need for novel, rapid, high throughput, accredited 
biotech solutions, particularly in the mass casualty setting. For guidance references, see TMT 
Handbook [79], including sub references from e.g., various ICRP publications. 
6. Conclusions 
Chemical or radiological mass casualties call for rapid and robust diagnostic technologies (Figure 
3). These should determine, monitor and assist in handling of the exposed. As indicated in this review 
the development of new and improved medical technologies utilizing recent developments within 
medicine, biotechnology and intelligent communication technology (ICT) is foreseen. New insights 
into useful biomarkers and the development of useful analytical technologies or concepts are 
reciprocally dependent and driven by “curiosity” or scientific incitements. Sometimes the scientific 
push giving new biomarkers or new analytical technology also results in medically useful devices. 
Figure 3. The intrinsic logistics of such development towards different diagnostic tools is 
simplified in the block diagram below. 
 
These devices are basically analytical instruments calibrated and somewhat modified to better serve 
their intended medical purpose and to be a useful property of the advanced hospital laboratory. 
Diagnostic tools as indicated in the figure, refers to mass produced (i.e., relatively cheap) simplified 
instruments that may serve as a standalone capability in acute care or in primary medical care. These 
are dedicated to simple routine analyses, such as blood glucose assessments. Finally, the triage tool is 
the instrument similarly dedicated to emergency medicine and mass casualties. It must be robust, Int. J. Environ. Res. Public Health 2011, 8 
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simple, efficient and cheap in order to be produced and implemented. The development of diagnostic 
and/or triage tools will depend on commercial realities. If there is a market, these tools will eventually 
appear when the technological advancements so allow. If the market is lacking, which is the case for 
such rare events as mass emergencies, such development has to be politically augmented and realized 
through public investments. 
The present review deals with the prospect of and need for diagnostic or triage tools when handling 
mass casualty situations following the exposure to toxic chemicals or radiation. The development of 
diagnostic principles for radiation damage and/or signs of intoxication have been dealt with in parallel. 
Obviously, the support and need for diagnostic tools within such professions as nuclear medicine, 
hematology and oncology has been larger than the corresponding support for development of diagnostic 
tools for intoxication. Biomarkers and diagnostically useful methods have, therefore, been developed 
for the assessment of dose effects and radiation injuries. None of these methods have as yet become a 
candidate for triage tool development. The development of diagnostic tools for intoxication is lagging 
behind. There may have been less support and/or need for this development and, indeed, there are less 
professionals involved in issues of intoxications in a clinical setting, i.e., involved in triage like situations. 
This review underlines the relative maturity of the underpinning science, i.e., about biomarkers, 
analytical procedures and miniaturization. The challenge now is to develop diagnostic assays, 
diagnostic tools and triage tools based on bodily fluids and/or cells that assess chemical exposure or 
already absorbed doses of ionizing radiation or deposited internal radiological contamination and 
simplified and miniaturized into useful triage tools. At the same time, diagnostic technologies 
assessing physiological functions that are altered by e.g., chemical or radiological exposures has to be 
developed as an integral tool in the medical management of casualties. In the end this becomes a 
question of resources and priorities. Making our society more resilient towards accidental or 
intentional release of toxic chemicals or radioactive material has to become an issue of high priority. 
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